Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?
Rusalatide acetate (Chrysalin®) is an investigational drug being evaluated for treatment of chronic wounds and fractures. Rusalatide acetate interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. Ru...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on pharmacotherapy 2008-10, Vol.9 (15), p.2717-2726 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2726 |
|---|---|
| container_issue | 15 |
| container_start_page | 2717 |
| container_title | Expert opinion on pharmacotherapy |
| container_volume | 9 |
| creator | Carney, Darrell H Olszewska-Pazdrak, Barbara |
| description | Rusalatide acetate (Chrysalin®) is an investigational drug being evaluated for treatment of chronic wounds and fractures. Rusalatide acetate interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. Rusalatide acetate significantly accelerated healing of diabetic foot ulcers and distal radius fractures in Phase I/II clinical trials. Subsequently, in one of the largest Phase III fracture studies to date, rusalatide acetate showed significant acceleration of distal radius fracture healing radiographically but failed to meet its primary clinical endpoint - time to removal of immobilization - within the intent-to-treat population. Subset analysis showed that rusalatide acetate met this primary clinical endpoint and significantly accelerated radiographic healing in osteopenic women. Rusalatide acetate may therefore show its greatest efficacy in healing-impaired patients. |
| doi_str_mv | 10.1517/14656566.9.15.2717 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_18803458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>744621457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-f496bd33dae4c4e7653857d0cd4d5f26f4222fcceef1330753b94953eca2b0793</originalsourceid><addsrcrecordid>eNp9kUuLFDEUhQtRnHH0D7iQrHRVbd6pAkWk8QUDbnQdUsmNnSFdafNA5t-btlvETZNFcsJ3bsI5w_Cc4A0RRL0mXIq-5GbuekMVUQ-Ga6I4H5WU8mE_d2A8ElfDk1LuMKZ4FvzxcEWmCTMupuvBblOLDuVWTDQ1OEDGQjUV0AKo7gD5VlsG5HL7gZJHdpeC7bcpIxfMAjXYLlJFLVrIBZnVIZ-N_WPKcDAhv3s6PPImFnh23m-G7x8_fNt-Hm-_fvqyfX87Ws5xHT2f5eIYcwa45aCkYJNQDlvHnfBUek4p9dYCeMIYVoItM58FA2vogtXMboZXp7mHnH42KFXvQ7EQo1khtaJ7MpISLlQnX14k5SwmITjtID2BNqdSMnh9yGFv8r0mWB9L0H9L0HPX-lhCN704T2_LHtw_yzn1Drw9AWHtQe7Nr5Sj09Xcx5R7eKsNRbOLD7z5z78DE-vOmgz6LrW89pAv_e83FcypeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69585542</pqid></control><display><type>article</type><title>Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Carney, Darrell H ; Olszewska-Pazdrak, Barbara</creator><creatorcontrib>Carney, Darrell H ; Olszewska-Pazdrak, Barbara</creatorcontrib><description>Rusalatide acetate (Chrysalin®) is an investigational drug being evaluated for treatment of chronic wounds and fractures. Rusalatide acetate interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. Rusalatide acetate significantly accelerated healing of diabetic foot ulcers and distal radius fractures in Phase I/II clinical trials. Subsequently, in one of the largest Phase III fracture studies to date, rusalatide acetate showed significant acceleration of distal radius fracture healing radiographically but failed to meet its primary clinical endpoint - time to removal of immobilization - within the intent-to-treat population. Subset analysis showed that rusalatide acetate met this primary clinical endpoint and significantly accelerated radiographic healing in osteopenic women. Rusalatide acetate may therefore show its greatest efficacy in healing-impaired patients.</description><identifier>ISSN: 1465-6566</identifier><identifier>EISSN: 1744-7666</identifier><identifier>DOI: 10.1517/14656566.9.15.2717</identifier><identifier>PMID: 18803458</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Amino Acid Sequence ; angiogenesis ; chronic wounds ; Clinical Trials as Topic ; Diabetic Foot - drug therapy ; diabetic foot ulcers ; endothelial dysfunction ; Fracture Healing - drug effects ; fracture repair ; Humans ; Molecular Sequence Data ; osteoporosis ; Peptide Fragments - adverse effects ; Peptide Fragments - chemistry ; Peptide Fragments - pharmacokinetics ; Peptide Fragments - pharmacology ; Peptide Fragments - therapeutic use ; rusalatide acetate ; Thrombin - adverse effects ; Thrombin - chemistry ; Thrombin - pharmacokinetics ; Thrombin - pharmacology ; Thrombin - therapeutic use</subject><ispartof>Expert opinion on pharmacotherapy, 2008-10, Vol.9 (15), p.2717-2726</ispartof><rights>Informa UK Ltd 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-f496bd33dae4c4e7653857d0cd4d5f26f4222fcceef1330753b94953eca2b0793</citedby><cites>FETCH-LOGICAL-c440t-f496bd33dae4c4e7653857d0cd4d5f26f4222fcceef1330753b94953eca2b0793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/14656566.9.15.2717$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/14656566.9.15.2717$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,59646,59752,60435,60541</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18803458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carney, Darrell H</creatorcontrib><creatorcontrib>Olszewska-Pazdrak, Barbara</creatorcontrib><title>Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?</title><title>Expert opinion on pharmacotherapy</title><addtitle>Expert Opin Pharmacother</addtitle><description>Rusalatide acetate (Chrysalin®) is an investigational drug being evaluated for treatment of chronic wounds and fractures. Rusalatide acetate interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. Rusalatide acetate significantly accelerated healing of diabetic foot ulcers and distal radius fractures in Phase I/II clinical trials. Subsequently, in one of the largest Phase III fracture studies to date, rusalatide acetate showed significant acceleration of distal radius fracture healing radiographically but failed to meet its primary clinical endpoint - time to removal of immobilization - within the intent-to-treat population. Subset analysis showed that rusalatide acetate met this primary clinical endpoint and significantly accelerated radiographic healing in osteopenic women. Rusalatide acetate may therefore show its greatest efficacy in healing-impaired patients.</description><subject>Amino Acid Sequence</subject><subject>angiogenesis</subject><subject>chronic wounds</subject><subject>Clinical Trials as Topic</subject><subject>Diabetic Foot - drug therapy</subject><subject>diabetic foot ulcers</subject><subject>endothelial dysfunction</subject><subject>Fracture Healing - drug effects</subject><subject>fracture repair</subject><subject>Humans</subject><subject>Molecular Sequence Data</subject><subject>osteoporosis</subject><subject>Peptide Fragments - adverse effects</subject><subject>Peptide Fragments - chemistry</subject><subject>Peptide Fragments - pharmacokinetics</subject><subject>Peptide Fragments - pharmacology</subject><subject>Peptide Fragments - therapeutic use</subject><subject>rusalatide acetate</subject><subject>Thrombin - adverse effects</subject><subject>Thrombin - chemistry</subject><subject>Thrombin - pharmacokinetics</subject><subject>Thrombin - pharmacology</subject><subject>Thrombin - therapeutic use</subject><issn>1465-6566</issn><issn>1744-7666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUuLFDEUhQtRnHH0D7iQrHRVbd6pAkWk8QUDbnQdUsmNnSFdafNA5t-btlvETZNFcsJ3bsI5w_Cc4A0RRL0mXIq-5GbuekMVUQ-Ga6I4H5WU8mE_d2A8ElfDk1LuMKZ4FvzxcEWmCTMupuvBblOLDuVWTDQ1OEDGQjUV0AKo7gD5VlsG5HL7gZJHdpeC7bcpIxfMAjXYLlJFLVrIBZnVIZ-N_WPKcDAhv3s6PPImFnh23m-G7x8_fNt-Hm-_fvqyfX87Ws5xHT2f5eIYcwa45aCkYJNQDlvHnfBUek4p9dYCeMIYVoItM58FA2vogtXMboZXp7mHnH42KFXvQ7EQo1khtaJ7MpISLlQnX14k5SwmITjtID2BNqdSMnh9yGFv8r0mWB9L0H9L0HPX-lhCN704T2_LHtw_yzn1Drw9AWHtQe7Nr5Sj09Xcx5R7eKsNRbOLD7z5z78DE-vOmgz6LrW89pAv_e83FcypeQ</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Carney, Darrell H</creator><creator>Olszewska-Pazdrak, Barbara</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>20081001</creationdate><title>Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?</title><author>Carney, Darrell H ; Olszewska-Pazdrak, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-f496bd33dae4c4e7653857d0cd4d5f26f4222fcceef1330753b94953eca2b0793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Amino Acid Sequence</topic><topic>angiogenesis</topic><topic>chronic wounds</topic><topic>Clinical Trials as Topic</topic><topic>Diabetic Foot - drug therapy</topic><topic>diabetic foot ulcers</topic><topic>endothelial dysfunction</topic><topic>Fracture Healing - drug effects</topic><topic>fracture repair</topic><topic>Humans</topic><topic>Molecular Sequence Data</topic><topic>osteoporosis</topic><topic>Peptide Fragments - adverse effects</topic><topic>Peptide Fragments - chemistry</topic><topic>Peptide Fragments - pharmacokinetics</topic><topic>Peptide Fragments - pharmacology</topic><topic>Peptide Fragments - therapeutic use</topic><topic>rusalatide acetate</topic><topic>Thrombin - adverse effects</topic><topic>Thrombin - chemistry</topic><topic>Thrombin - pharmacokinetics</topic><topic>Thrombin - pharmacology</topic><topic>Thrombin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carney, Darrell H</creatorcontrib><creatorcontrib>Olszewska-Pazdrak, Barbara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Expert opinion on pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carney, Darrell H</au><au>Olszewska-Pazdrak, Barbara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?</atitle><jtitle>Expert opinion on pharmacotherapy</jtitle><addtitle>Expert Opin Pharmacother</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>9</volume><issue>15</issue><spage>2717</spage><epage>2726</epage><pages>2717-2726</pages><issn>1465-6566</issn><eissn>1744-7666</eissn><abstract>Rusalatide acetate (Chrysalin®) is an investigational drug being evaluated for treatment of chronic wounds and fractures. Rusalatide acetate interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. Rusalatide acetate significantly accelerated healing of diabetic foot ulcers and distal radius fractures in Phase I/II clinical trials. Subsequently, in one of the largest Phase III fracture studies to date, rusalatide acetate showed significant acceleration of distal radius fracture healing radiographically but failed to meet its primary clinical endpoint - time to removal of immobilization - within the intent-to-treat population. Subset analysis showed that rusalatide acetate met this primary clinical endpoint and significantly accelerated radiographic healing in osteopenic women. Rusalatide acetate may therefore show its greatest efficacy in healing-impaired patients.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>18803458</pmid><doi>10.1517/14656566.9.15.2717</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-6566 |
| ispartof | Expert opinion on pharmacotherapy, 2008-10, Vol.9 (15), p.2717-2726 |
| issn | 1465-6566 1744-7666 |
| language | eng |
| recordid | cdi_pubmed_primary_18803458 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Amino Acid Sequence angiogenesis chronic wounds Clinical Trials as Topic Diabetic Foot - drug therapy diabetic foot ulcers endothelial dysfunction Fracture Healing - drug effects fracture repair Humans Molecular Sequence Data osteoporosis Peptide Fragments - adverse effects Peptide Fragments - chemistry Peptide Fragments - pharmacokinetics Peptide Fragments - pharmacology Peptide Fragments - therapeutic use rusalatide acetate Thrombin - adverse effects Thrombin - chemistry Thrombin - pharmacokinetics Thrombin - pharmacology Thrombin - therapeutic use |
| title | Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Could%20rusalatide%20acetate%20be%20the%20future%20drug%20of%20choice%20for%20diabetic%20foot%20ulcers%20and%20fracture%20repair?&rft.jtitle=Expert%20opinion%20on%20pharmacotherapy&rft.au=Carney,%20Darrell%20H&rft.date=2008-10-01&rft.volume=9&rft.issue=15&rft.spage=2717&rft.epage=2726&rft.pages=2717-2726&rft.issn=1465-6566&rft.eissn=1744-7666&rft_id=info:doi/10.1517/14656566.9.15.2717&rft_dat=%3Cproquest_pubme%3E744621457%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69585542&rft_id=info:pmid/18803458&rfr_iscdi=true |